MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits - Regeneron Pharmaceuticals ( NASDAQ:REGN ) , MAIA Biotechnology ( AMEX:MAIA )
MAIA Biotechnology Inc. MAIA, a clinical-stage biopharmaceutical company focused on developing and commercializing targeted immunotherapies for cancer, reported positive interim survival benefits in a phase 2 study of THIO, its lead therapy to fight advanced non-small cell lung cancer ( NSCLC ) .
| Ticker |
Sentiment |
Impact |
|
REGN
|
Neutral
|
11 %
|
|
SSTK
|
Neutral
|
6 %
|
